Journal of International Oncology ›› 2020, Vol. 47 ›› Issue (6): 346-350.doi: 10.3760/cma.j.cn371439-20191112-00033
• Orginal Articles • Previous Articles Next Articles
Zhou Luqiu, Liu Xianxi, Li Yan, Mao Xiguang()
Received:
2019-11-12
Revised:
2020-02-28
Online:
2020-06-08
Published:
2020-07-22
Contact:
Mao Xiguang
E-mail:mxg6639@163.com
Zhou Luqiu, Liu Xianxi, Li Yan, Mao Xiguang. Analysis of prognostic risk factors of type Ⅰ endometrial cancer[J]. Journal of International Oncology, 2020, 47(6): 346-350.
"
临床特征 | 例数(%) | 临床特征 | 例数(%) |
---|---|---|---|
年龄(岁) | 肥胖 | ||
<50 | 120(43.0) | 是 | 89(31.9) |
≥50 | 159(57.0) | 否 | 190(68.1) |
高血压 | 糖尿病 | ||
有 | 72(25.8) | 有 | 76(27.2) |
无 | 207(74.2) | 无 | 203(72.8) |
组织学分级 | 手术-病理分期 | ||
G1 | 166(59.5) | Ⅰ | 218(78.1) |
G2 | 88(31.5) | Ⅱ | 23(8.2) |
G3 | 25(9.0) | Ⅲ | 38(13.6) |
肿瘤大小(cm) | 腹腔细胞学 | ||
≥2 | 151(54.1) | 阳性 | 60(21.5) |
<2 | 128(45.9) | 阴性 | 219(78.5) |
淋巴结切除 | 淋巴结性质a | ||
是 | 227(81.4) | 阳性 | 11(4.8) |
否 | 52(18.6) | 阴性 | 216(95.2) |
宫颈间质浸润 | 附件转移 | ||
是 | 36(12.9) | 是 | 28(10.0) |
否 | 243(87.1) | 否 | 251(90.0) |
淋巴血管间隙浸润 | 肌层浸润深度 | ||
是 | 32(11.5) | ≥1/2 | 67(24.0) |
否 | 247(88.5) | <1/2 | 212(76.0) |
"
变量 | HR值 | 95%CI | P值 |
---|---|---|---|
年龄 | 2.096 | 0.916~4.796 | 0.080 |
高血压 | 1.797 | 0.822~3.936 | 0.142 |
肥胖 | 2.194 | 1.031~4.671 | 0.041 |
糖尿病 | 1.896 | 0.879~4.088 | 0.103 |
肌层浸润深度 | 2.957 | 1.382~6.329 | 0.005 |
组织学分级 | |||
G1 | 1 | - | - |
G2 | 3.271 | 1.336~8.010 | 0.010 |
G3 | 9.933 | 3.565~27.672 | <0.001 |
肿瘤大小 | 8.067 | 2.426~26.821 | 0.001 |
腹腔细胞学 | 3.293 | 1.523~7.121 | 0.002 |
手术-病理分期 | |||
Ⅰ | 1 | - | - |
Ⅱ | 2.693 | 0.589~12.317 | 0.202 |
Ⅲ | 28.357 | 11.516~69.828 | <0.001 |
淋巴结切除 | 6.900 | 0.936~50.857 | 0.058 |
淋巴结性质a | 14.629 | 5.023~42.606 | <0.001 |
宫颈间质浸润 | 3.806 | 1.653~8.764 | 0.002 |
附件转移 | 9.101 | 3.831~21.622 | <0.001 |
淋巴血管间隙浸润 | 5.011 | 2.233~11.249 | <0.001 |
术后辅助治疗 | 0.828 | 0.635~1.079 | 0.163 |
手术方式 | 1.142 | 0.844~1.545 | 0.389 |
"
变量 | HR值 | 95%CI | P值 |
---|---|---|---|
肥胖 | 0.510 | 0.216~1.206 | 0.125 |
肌层浸润深度 | 2.503 | 1.115~5.616 | 0.026 |
组织学分级(G1) | 1 | - | - |
组织学分级(G2) | 3.143 | 1.205~8.198 | 0.019 |
组织学分级(G3) | 3.655 | 1.151~11.610 | 0.028 |
肿瘤大小 | 0.399 | 0.103~1.555 | 1.860 |
腹腔细胞学 | 1.298 | 0.510~3.306 | 0.584 |
手术-病理分期(Ⅰ期) | 1 | - | - |
手术-病理分期(Ⅱ期) | 1.368 | 0.277~6.755 | 0.701 |
手术-病理分期(Ⅲ期) | 27.701 | 9.608~79.869 | <0.001 |
淋巴结性质 | 1.169 | 0.292~4.677 | 0.825 |
宫颈间质浸润 | 1.436 | 0.335~26.709 | 0.626 |
附件转移 | 5.065 | 0.961~26.709 | 0.056 |
淋巴血管间隙浸润 | 3.297 | 1.370~7.936 | 0.008 |
[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492.
doi: 10.3322/caac.21492 pmid: 30207593 |
[2] |
Morice P, Leary A, Creutzberg C, et al. Endometrial cancer[J]. Lancet, 2016,387(10023):1094-1108. DOI: 10.1016/S0140-6736(15)00130-0.
doi: 10.1016/S0140-6736(15)00130-0 pmid: 26354523 |
[3] |
Takahashi A, Matsuura M, Matoda M, et al. Clinicopathological features of early and late recurrence of endometrial carcinoma after surgical resection[J]. Int J Gynecol Cancer, 2017,27(5):967-972. DOI: 10.1097/IGC.0000000000000984.
doi: 10.1097/IGC.0000000000000984 pmid: 28486241 |
[4] |
Han KH, Kim HS, Lee M, et al. Prognostic factors for tumor recu-rrence in endometrioid endometrial cancer stages ⅠA and ⅠB[J]. Medicine (Baltimore), 2017,96(21):e6976. DOI: 10.1097/MD.0000000000006976.
doi: 10.1097/MD.0000000000006976 |
[5] |
dos Reis R, Burzawa JK, Tsunoda AT, et al. Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer[J]. Int J Gynecol Cancer, 2015,25(7):1292-1299. DOI: 10.1097/IGC.0000000000000490.
doi: 10.1097/IGC.0000000000000490 pmid: 26067863 |
[6] |
Wright JD, Huang Y, Burke WM, et al. Influence of lymphadenectomy on survival for early-stage endometrial cancer[J]. Obstet Gynecol, 2016,127(1):109-118. DOI: 10.1097/AOG.00000000-00001194.
doi: 10.1097/AOG.0000000000001194 pmid: 26646130 |
[7] |
Turan T, Kimyon Comert G, Turkmen O, et al. Therapeutic value of lymphadenectomy and adjuvant radiotherapy in uterine corpus confined endometrioid-type cancer[J]. J Chin Med Assoc, 2018,81(8):714-723. DOI: 10.1016/j.jcma.2017.05.014.
doi: 10.1016/j.jcma.2017.05.014 pmid: 29287700 |
[8] |
Chi DS, Barakat RR, Palayekar MJ, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology[J]. Int J Gynecol Cancer, 2008,18(2):269-273. DOI: 10.1111/j.1525-1438.2007.00996.x.
doi: 10.1111/j.1525-1438.2007.00996.x pmid: 18334008 |
[9] |
Barton DP, Naik R, Herod J. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC Trial): a randomized study[J]. Int J Gynecol Cancer, 2009,19(8):1465. DOI: 10.1111/IGC.0b013e3181b89f95.
doi: 10.1111/IGC.0b013e3181b89f95 pmid: 19893425 |
[10] |
Sundar S, Balega J, Crosbie E, et al. BGCS uterine cancer guidelines: recommendations for practice[J]. Eur J Obstet Gynecol Reprod Biol, 2017,213:71-97. DOI: 10.1016/j.ejogrb.2017.04.015.
doi: 10.1016/j.ejogrb.2017.04.015 pmid: 28437632 |
[11] |
Geppert B Lönnerfors C Bollino M, et al. Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications [J]. Gynecol Oncol, 2018,148(3):491-498. DOI: 10.1016/j.ygyno.2017.12.017.
doi: 10.1016/j.ygyno.2017.12.017 pmid: 29273307 |
[12] |
Singh N, Hirschowitz L, Zaino R, et al. Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade) [J]. Int J Gynecol Pathol, 2019,38 Suppl 1: S93-S113. DOI: 10.1097/PGP.0000000000000524.
doi: 10.1097/PGP.0000000000000524 |
[13] |
Dane C, Bakir S. The effect of myometrial invasion on prognostic factors and survival analysis in endometrial carcinoma[J]. Afr Health Sci, 2019,19(4):3235-3241. DOI: 10.4314/ahs.v19i4.47.
doi: 10.4314/ahs.v19i4.47 pmid: 32127901 |
[14] |
Tanaka K, Kobayashi Y, Sugiyama J, et al. Histologic grade and peritoneal cytology as prognostic factors in type 1 endometrial cancer[J]. Int J Clin Oncol, 2017,22(3):533-540. DOI: 10.1007/s10147-016-1079-5.
doi: 10.1007/s10147-016-1079-5 pmid: 28083737 |
[15] |
Widschwendter P, Bauer E, De Gregorio N, et al. Influence of prognostic factors on lymph node involvement in endometrial cancer: a single-center experience[J]. Int J Gynecol Cancer, 2018,28(6):1145-1152. DOI: 10.1097/IGC.0000000000001290.
doi: 10.1097/IGC.0000000000001290 pmid: 29757871 |
[16] | Imboden S, Mereu L, Siegenthaler F, et al. Oncological safety and perioperative morbidity in low-risk endometrial cancer with sentinel lymph-node dissection[J]. Eur J Surgl Oncol, 2019,45(9):1638-1643. DOI: 10.1016/j.ejso.2019.05.026. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[4] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[5] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[6] | Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[7] | Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[8] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[9] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[10] | Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[11] | Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[12] | Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[13] | Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64. |
[14] | Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469. |
[15] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||